Metastatic Melanoma Clinical Trials

29 studies are recruiting for metastatic melanoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Los Angeles, California 7 New York, New York 6 Pittsburgh, Pennsylvania 6 Columbus, Ohio 5 St Louis, Missouri 5 Chicago, Illinois 4 Houston, Texas 4 Madison, Wisconsin 4 Miami, Florida 4 Orlando, Florida 4 Salt Lake City, Utah 4 Aurora, Colorado 3 Bethesda, Maryland 3 Cincinnati, Ohio 3 Jacksonville, Florida 3 Lexington, Kentucky 3 Louisville, Kentucky 3 Minneapolis, Minnesota 3 Nashville, Tennessee 3 Portland, Oregon 3 Rochester, Minnesota 3

Studies, page 2

  1. Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

    This is a phase 1 dose-escalation study of nilotinib in combination with fixed-dose dabrafenib and trametinib regimen for patients with metastatic or unresectable melanoma carrying a BRAF V600 mutation and have relapsed on a BRAF/MEK inhibitor therapy. The goal is to assess the toxicity and tolerab…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Markey Cancer Center, Lexington, Kentucky
    Locations
    4 in total
    Run by
    Rina Plattner

    See if you can join NCT04903119 on ClinicalTrials.gov

  2. A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

    This is a noninterventional, observational, long-term follow-up (LTFU) study. Patients in this study will be followed for 5 years from enrollment on this study to assess potential delayed risks of RPx products. Eligible participants for this LTFU study include patients who received at least 1 dose …

    Stage
    Not phased
    Ages
    18 and older
    Site
    UC San Diego Moores Cancer Center, La Jolla, California
    Locations
    2 in total
    Run by
    Replimune, Inc.

    See if you can join NCT06887348 on ClinicalTrials.gov

  3. Mirdametinib in Patients With Advanced NF1-mutant Melanoma

    The goal of this clinical trial is to evaluate clinical efficacy of mirdametinib in patients with advanced NF1-mutant melanoma whose disease has progressed while on or after previous immunotherapy. The main questions this study aims to answer are: * To evaluate the feasibility of conducting a prosp…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    California Pacific Medical Center - Sutter Health, San Francisco, California
    Run by
    Kevin Kim, MD

    See if you can join NCT07237100 on ClinicalTrials.gov

  4. In Vivo Liquid Biopsy of Melanoma (Cytophone)

    The Cytophone is a first in the world patented system to identify and count single circulating melanoma cells in blood circulation inside the human body. The Cytophone has a unique capability to find rare melanoma cells in the blood by an assessment of 100-500 times greater amounts of blood volume …

    Stage
    Not phased
    Ages
    18 to 80
    Site
    SSM Health Dean Medical Group Specialty Services, Madison, Wisconsin
    Run by
    Cytoastra

    See if you can join NCT06488365 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.